1403898-61-2

Usage

Uses

Used in Pharmaceutical Industry:
(R)-2-((S)-2-benzyloxycarbonylamino-3-hydroxy-propionyl-amino)propionic acid methyl ester is used as an intermediate in the synthesis of complex pharmaceutical compounds for various therapeutic applications. Its unique structure and protected amine group make it a valuable building block in the development of new drugs.
Used in Organic Chemistry Research:
In the field of organic chemistry, (R)-2-((S)-2-benzyloxycarbonylamino-3-hydroxy-propionyl-amino)propionic acid methyl ester serves as a key compound for studying the properties and reactivity of chiral centers and amino acid derivatives. Its complex structure allows researchers to explore new reaction pathways and develop innovative synthetic methods.
Used in Peptide Synthesis:
(R)-2-((S)-2-benzyloxycarbonylamino-3-hydroxy-propionyl-amino)propionic acid methyl ester is used as a building block in the synthesis of peptides and peptide-based drugs. The protected amine group facilitates the stepwise assembly of peptide chains, enabling the creation of complex peptide structures with potential applications in medicine and biotechnology.
Used in Drug Development:
(R)-2-((S)-2-benzyloxycarbonylamino-3-hydroxy-propionyl-amino)propionic acid methyl ester is utilized in drug development as a potential lead molecule for the design of new therapeutic agents. Its unique structure and functional groups can be further modified to optimize its pharmacological properties, such as potency, selectivity, and bioavailability, for the treatment of various diseases and conditions.

Upstream product

• 1145-80-8 N-(benzyloxycarbonyl)-L-serine 
• 14316-06-4 D-alanine methyl ester hydrochloride 

Downstream Products

• 1403898-62-3 (3S,6R)-3-(hydroxymethyl)-6-methylpiperazine-2,5-dione 

Relevant academic research and scientific papers

Structure-based design and pharmacokinetic optimization of covalent allosteric inhibitors of the mutant gtpase krasg12c

Attempts to directly drug the important oncogene KRAS have met with limited success despite numerous efforts across industry and academia. The KRASG12C mutant represents an "Achilles heel" and has recently yielded to covalent targeting with small molecules that bind the mutant cysteine and create an allosteric pocket on GDP-bound RAS, locking it in an inactive state. A weak inhibitor at this site was optimized through conformational locking of a piperazine-quinazoline motif and linker modification. Subsequent introduction of a key methyl group to the piperazine resulted in enhancements in potency, permeability, clearance, and reactivity, leading to identification of a potent KRASG12C inhibitor with high selectivity and excellent cross-species pharmacokinetic parameters and in vivo efficacy.

CHEMICAL COMPOUNDS

The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY

The invention relates to new bicyclic heterocycle compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY

The invention relates to new bicyclic heterocycle compounds of formula (I): wherein R1 is seected from specific pyrazolyl, imidazolyl, pridinyl and triazolyl groups. The invention also realtes to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY

The invention relates to new bicyclic heterocycle compounds of formula (I): (Formula (I)), pharmaceutical compositions comprising said compounds and to use of said compounds in the treatment of diseases, e.g. cancer.

BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY

The invention relates to new bicyclic heterocycle compounds of formula (I):,to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.